These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21431104)

  • 1. Quantitative proteomic analysis in breast cancer.
    Tabchy A; Hennessy BT; Gonzalez-Angulo AM; Bernstam FM; Lu Y; Mills GB
    Drugs Today (Barc); 2011 Feb; 47(2):169-82. PubMed ID: 21431104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic classification of breast cancer.
    Kamel D; Brady B; Tabchy A; Mills GB; Hennessy B
    Curr Drug Targets; 2012 Nov; 13(12):1495-509. PubMed ID: 22974393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reverse phase protein arrays in signaling pathways: a data integration perspective.
    Creighton CJ; Huang S
    Drug Des Devel Ther; 2015; 9():3519-27. PubMed ID: 26185419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reverse phase protein microarrays advance to use in clinical trials.
    Mueller C; Liotta LA; Espina V
    Mol Oncol; 2010 Dec; 4(6):461-81. PubMed ID: 20974554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
    Jimenez CR; Verheul HM
    Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers].
    Gilabert M; Audebert S; Viens P; Borg JP; Bertucci F; Gonçalves A
    Bull Cancer; 2010 Mar; 97(3):321-39. PubMed ID: 20202919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
    Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
    Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration.
    Pignatelli J; Goswami S; Jones JG; Rohan TE; Pieri E; Chen X; Adler E; Cox D; Maleki S; Bresnick A; Gertler FB; Condeelis JS; Oktay MH
    Sci Signal; 2014 Nov; 7(353):ra112. PubMed ID: 25429076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse phase protein arrays: mapping the path towards personalized medicine.
    Gallagher RI; Espina V
    Mol Diagn Ther; 2014 Dec; 18(6):619-30. PubMed ID: 25358623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of reverse phase protein array for molecular classification of breast cancer.
    Negm OH; Muftah AA; Aleskandarany MA; Hamed MR; Ahmad DA; Nolan CC; Diez-Rodriguez M; Tighe PJ; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2016 Jan; 155(1):25-35. PubMed ID: 26661092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium.
    Hudelist G; Singer CF; Pischinger KI; Kaserer K; Manavi M; Kubista E; Czerwenka KF
    Proteomics; 2006 Mar; 6(6):1989-2002. PubMed ID: 16470630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine.
    Masuda M; Yamada T
    Biochim Biophys Acta; 2015 Jun; 1854(6):651-7. PubMed ID: 25448010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells.
    Sandhu C; Connor M; Kislinger T; Slingerland J; Emili A
    J Proteome Res; 2005; 4(3):674-89. PubMed ID: 15952714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.
    Sonnenblick A; Brohée S; Fumagalli D; Rothé F; Vincent D; Ignatiadis M; Desmedt C; Salgado R; Sirtaine N; Loi S; Neven P; Loibl S; Denkert C; Joensuu H; Piccart M; Sotiriou C
    Oncotarget; 2015 Oct; 6(30):30306-16. PubMed ID: 26358523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of functional proteomics in breast cancer.
    Chae YK; Gonzalez-Angulo AM
    Oncologist; 2014 Apr; 19(4):328-35. PubMed ID: 24664486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse phase protein microarrays for theranostics and patient-tailored therapy.
    Espina V; Wulfkuhle J; Calvert VS; Liotta LA; Petricoin EF
    Methods Mol Biol; 2008; 441():113-28. PubMed ID: 18370315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of proteomic technologies in breast cancer research.
    Mazur MG; Pyatchanina TV
    Exp Oncol; 2016 Sep; 38(3):146-57. PubMed ID: 27685521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue.
    Hudelist G; Pacher-Zavisin M; Singer CF; Holper T; Kubista E; Schreiber M; Manavi M; Bilban M; Czerwenka K
    Breast Cancer Res Treat; 2004 Aug; 86(3):281-91. PubMed ID: 15567944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic portrait of human breast cancer progression identifies novel prognostic markers.
    Geiger T; Madden SF; Gallagher WM; Cox J; Mann M
    Cancer Res; 2012 May; 72(9):2428-39. PubMed ID: 22414580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic analysis of tissue samples in translational breast cancer research.
    Gromov P; Moreira JM; Gromova I
    Expert Rev Proteomics; 2014 Jun; 11(3):285-302. PubMed ID: 24837673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.